Pharmacokinetic and Pharmacodynamic Assessment of Valganciclovir in Infants With Congenital Cytomegalovirus Infection
- 4 September 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 47 (3) , 393-399
Abstract
Background: Valganciclovir (VGCV) is administered at a dose of 16 mg/kg 2 times daily for 6 months to treat symptomatic congenital cytomegalovirus (CMV) infections. During the treatment period, approximately 20% of the patients developed grade 3 or higher neutropenia. Currently, information on the pharmacokinetics and pharmacodynamics of ganciclovir, an active metabolite of VGCV, in infants is limited. In the current study, the relationship between ganciclovir concentration and neutropenia was investigated, and a population pharmacokinetic (PPK) model of ganciclovir in infants with symptomatic congenital CMV infection was developed. Methods: Japanese infants who were prescribed oral VGCV for symptomatic congenital CMV infections between July 2017 and January 2021 were included. The relationship between the observed trough ganciclovir concentrations and neutrophil counts was examined. PPK analysis was performed to evaluate the covariates affecting the pharmacokinetics of ganciclovir. Results: Twenty-seven ganciclovir serum samples from 8 patients were analyzed. A moderate negative correlation was observed between the observed trough ganciclovir concentration and neutrophil count. PPK model analysis showed that postmenstrual age (PMA) affected the total body clearance of ganciclovir after correcting for the empirical allometric scaling of body weight. Based on PMA and body weight, a nomogram to achieve the target area under the concentration–time curve from 0 to 24 hours of 40–60 mcg·h·mL−1 of ganciclovir was calculated. Conclusions: The relationship between neutrophil count and ganciclovir trough concentration in infants was clarified. The PPK model showed that the dose of VGCV should be reduced in patients with a low PMA to achieve target exposure.Keywords
Funding Information
- Grant-in-Aid for Japan Research Foundation for Clinical Pharmacology
- Japan Agency for Medical Research and Development (JP22gk0110037 and JP23gn0110037)
This publication has 24 references indexed in Scilit:
- Assessment of patients’ characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus diseaseJournal of Infection and Chemotherapy, 2024
- Clinical outcome and the role of antivirals in congenital cytomegalovirus infectionAntiviral Research, 2021
- Efficacy, safety, and pharmacokinetics of oral valganciclovir in patients with congenital cytomegalovirus infectionJournal of Infection and Chemotherapy, 2021
- Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment FailureCPT: Pharmacometrics & Systems Pharmacology, 2018
- Bottom‐up Meets Top‐down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young ChildrenClinical Pharmacology & Therapeutics, 2016
- A Pharmacokinetic Standard for Babies and AdultsJournal of Pharmaceutical Sciences, 2013
- Ganciclovir Population Pharmacokinetics in Neonates Following Intravenous Administration of Ganciclovir and Oral Administration of a Liquid Valganciclovir FormulationClinical Pharmacology & Therapeutics, 2007
- A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: Noninvasive assessment of body composition and growthThe Journal of Pediatrics, 1986
- A simple estimate of glomerular filtration rate in adolescent boysThe Journal of Pediatrics, 1985
- A simple estimate of glomerular filtration ratein full-term infants during the first year of lifeThe Journal of Pediatrics, 1984